Endometrial Cancer
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (GS-US-682-6769)
- Details
ClinicalTrials.gov ID:
NCT06486441
Diagnosis Type:
NA
USOR Number:
- Address
,
P: